Af­ter Ru­bius col­lapse and brief stop at Flag­ship start­up, Pablo Cagnoni finds new start at In­cyte

Af­ter im­mers­ing in the risky start­up world for a decade, Pablo Cagnoni is tak­ing a top role at a big cap play­er.

In­cyte has tapped Cagnoni, a three-time biotech CEO, to fill the new­ly cre­at­ed role of pres­i­dent and head of R&D, putting him in charge of lead­ing and speed­ing up pro­grams across on­col­o­gy, hema­tol­ogy, in­flam­ma­to­ry and au­toim­mu­ni­ty, in­clud­ing der­ma­tol­ogy.

Cagnoni may be best known for lead­ing Ru­bius Ther­a­peu­tics, a flashy cell ther­a­py start­up out of Flag­ship, from its me­te­oric rise through ul­ti­mate col­lapse. But since No­vem­ber, he’s been CEO at a dif­fer­ent Flag­ship biotech, Laronde. His de­par­ture sets off a lead­er­ship shuf­fle at the com­pa­ny, which is fo­cused on what it calls “end­less RNA,” with chair­man John Mendlein be­com­ing in­ter­im CEO and Sutro Bio­phar­ma vet Trevor Hal­lam join­ing as CSO. Avak Kahve­jian, co-founder and in­ter­im CSO, will now be­come an ad­vi­sor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER